ReviewPolymers2023
Hyaluronic Acid-Based Nanocarriers for Anticancer Drug Delivery.
Review in Polymers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Article
- Evaluation of Histidine-Octamer-Modified Hyaluronic Acid as a Cytosolic Drug Delivery Material via CD44-Mediated Cellular Uptake and Endosomal Escape.Pharmaceutics · 2026Article
- Bridging Scales: Integrating Hyaluronan-Based Nanoencapsulation into 3D Hydrogel Constructs for Advanced Therapeutics-A Comprehensive Review.Gels (Basel, Switzerland) · 2026Review
- Cancer Drug Delivery with Nanoparticles and Biomolecules: Stimuli-Responsive, Theranostic, and AI-Guided Approaches.Materials (Basel, Switzerland) · 2026Review
- Iron oxide nanoparticles co-conjugated with hyaluronic acid and limonene trigger oxidative stress and cell cycle arrest in triple-negative breast cancer.Medical oncology (Northwood, London, England) · 2026Article
- Synergistic and Selective Antiproliferative Effects of Cafestol and a Hyaluronic Acid-Epigallocatechin Gallate Conjugate in Human Renal Cancer Cells.International journal of molecular sciences · 2026Article
- Hyaluronic acid/kaempferol-functionalized Fe₃O₄ nanoparticles promote ROS-associated apoptosis and modulate caspase-8/BCRT1 axis in triple-negative breast cancer.Scientific reports · 2026Article
- Aptamer-Functionalized Nanocarriers for Bone and Joint Diseases: Engineering Design Rules and Translational Roadmap.Small science · 2026Article
- Nano-encapsulatedRSC advances · 2026Article
- Hyaluronic Acid-Phospholipid Hybrid Nanocarriers (Hyalutocosomes) for Enhanced Dermal Delivery of Vitamin E and Photoprotection.Scientific reports · 2026Article
- Dietary Supplements in Public Health: Benefits, Risks, and Emerging Gel/Hydrogel Delivery Systems.Gels (Basel, Switzerland) · 2026Review
- Role of nanotechnology in modulating the tumor microenvironment to enhance immunotherapy efficacy.World journal of clinical oncology · 2026Review
- Review
- Bio-based nanophotothermal systems as smart drug delivery platforms for multimodal synergistic cancer therapy-a review.Frontiers in medical technology · 2026Review
- Recent Advances in Novel Drug Delivery Systems for the Management of Cutaneous Squamous Cell Carcinoma.International journal of nanomedicine · 2026Review
- Targeted nano-drug delivery systems for tumor immunotherapy.Journal of pharmaceutical analysis · 2026Review
- Next-generation nanomedicine for cancer therapy: advances, challenges, and future perspectives.Frontiers in chemistry · 2026Review
- Hyaluronic acid-engineered milk extracellular vesicles to target triple negative breast cancer through CD44.Pharmaceutical biology · 2025Article
- Advancement in nanocarrier-mediated delivery of herbal bioactives: from bench to beside.Natural products and bioprospecting · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hyaluronic acid (HA), a main component of the extracellular matrix, is widely utilized to deliver anticancer drugs due to its biocompatibility, biodegradability, non-toxicity, non-immunogenicity and numerous modification sites, such as carboxyl and hydroxyl groups. Moreover, HA serves as a natural ligand for tumor-targeted drug delivery systems, as it contains the endocytic HA receptor, CD44, which is overexpressed in many cancer cells. Therefore, HA-based nanocarriers have been developed to improve drug delivery efficiency and distinguish between healthy and cancerous tissues, resulting in reduced residual toxicity and off-target accumulation. This article comprehensively reviews the fabrication of anticancer drug nanocarriers based on HA in the context of prodrugs, organic carrier materials (micelles, liposomes, nanoparticles, microbubbles and hydrogels) and inorganic composite nanocarriers (gold nanoparticles, quantum dots, carbon nanotubes and silicon dioxide). Additionally, the progress achieved in the design and optimization of these nanocarriers and their effects on cancer therapy are discussed. Finally, the review provides a summary of the perspectives, the lessons learned so far and the outlook towards further developments in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.